» Articles » PMID: 31641426

Diabetic Cardiomyopathy: Pathophysiology, Theories and Evidence to Date

Overview
Specialty Endocrinology
Date 2019 Oct 24
PMID 31641426
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of type 2 diabetes (T2D) has increased worldwide and doubled over the last two decades. It features among the top 10 causes of mortality and morbidity in the world. Cardiovascular disease is the leading cause of complications in diabetes and within this, heart failure has been shown to be the leading cause of emergency admissions in the United Kingdom. There are many hypotheses and well-evidenced mechanisms by which diabetic cardiomyopathy as an entity develops. This review aims to give an overview of these mechanisms, with particular emphasis on metabolic inflexibility. T2D is associated with inefficient substrate utilisation, an inability to increase glucose metabolism and dependence on fatty acid oxidation within the diabetic heart resulting in mitochondrial uncoupling, glucotoxicity, lipotoxicity and initially subclinical cardiac dysfunction and finally in overt heart failure. The review also gives a concise update on developments within clinical imaging, specifically cardiac magnetic resonance studies to characterise and phenotype early cardiac dysfunction in T2D. A better understanding of the pathophysiology involved provides a platform for targeted therapy in diabetes to prevent the development of early heart failure with preserved ejection fraction.

Citing Articles

The impact of diabetes on tight junctions in cardiomyopathy dysfunction.

Chodari L, Fatehfar S, Ahmadi M, Ghorbanzadeh V J Diabetes Metab Disord. 2024; 23(2):1645-1651.

PMID: 39610492 PMC: 11599488. DOI: 10.1007/s40200-024-01469-5.


Subclinical Left Ventricular Dysfunction over Seven-Year Follow-Up in Type 2 Diabetes Patients without Cardiovascular Diseases.

Akasheva D, Utina T, Dzhioeva O, Drapkina O Biomedicines. 2024; 12(9).

PMID: 39335545 PMC: 11428263. DOI: 10.3390/biomedicines12092031.


The change of epicardial adipose tissue characteristics and vulnerability for atrial fibrillation upon drastic weight loss.

Meulendijks E, Janssen-Telders C, Hulsman E, Lobe N, Zappala P, Terpstra M Adipocyte. 2024; 13(1):2395565.

PMID: 39248109 PMC: 11385166. DOI: 10.1080/21623945.2024.2395565.


Endogenous adenine is a potential driver of the cardiovascular-kidney-metabolic syndrome.

Tamayo I, Lee H, Aslam M, Liu J, Ragi N, Karanam V medRxiv. 2024; .

PMID: 39228698 PMC: 11370547. DOI: 10.1101/2024.08.19.24312277.


CircRNA_012164/MicroRNA-9-5p axis mediates cardiac fibrosis in diabetic cardiomyopathy.

Wang H, Wang E, Feng B, Chakrabarti S PLoS One. 2024; 19(7):e0302772.

PMID: 39042659 PMC: 11265710. DOI: 10.1371/journal.pone.0302772.


References
1.
Khan J, Wilmot E, Leggate M, Singh A, Yates T, Nimmo M . Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. Eur Heart J Cardiovasc Imaging. 2014; 15(11):1263-9. DOI: 10.1093/ehjci/jeu121. View

2.
Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

3.
Camici P, Marraccini P, Marzilli M, Lorenzoni R, Buzzigoli G, Puntoni R . Coronary hemodynamics and myocardial metabolism during and after pacing stress in normal humans. Am J Physiol. 1989; 257(3 Pt 1):E309-17. DOI: 10.1152/ajpendo.1989.257.3.E309. View

4.
Unger R . Lipotoxic diseases. Annu Rev Med. 2002; 53:319-36. DOI: 10.1146/annurev.med.53.082901.104057. View

5.
Savage D, Levy D, Dannenberg A, Garrison R, CASTELLI W . Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol. 1990; 65(5):371-6. DOI: 10.1016/0002-9149(90)90304-j. View